PTC rises after Roche starts SMA trial

Roche (SIX:ROG; OTCQX:RHHBY) is recruiting patients for a Phase II trial of RG7916 to treat spinal muscular atrophy, according to an update posted Thursday to a ClinicalTrials.gov entry. Roche has rights to the candidate from PTC Therapeutics Inc. (NASDAQ:PTCT) under a 2011 agreement.

RG7916 is a survival of motor neuron 2 centromeric ( SMN2) splicing modifier. ...